Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of TQB3820 in R/R MM or R/R Indolent B-NHL
NCT05020639Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2021
- Primary completion
- Aug 2024
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3820 in multiple myeloma (MM) and B-cell non-Hodgkin lymphoma, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose-limiting toxicity up to 18 months, Maximum Tolerated Dose up to 18 months and 2 more. Status: unknown.
02
Drugs
TQB3820
03
Conditions
multiple myeloma (MM)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05020639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05020639.